Cita APA (7a ed.)
Marks, J. R., Zhang, D., Hardman, T., Chen, Y., Hall, A., Simpson, L., . . . Hwang, E. S. (2025). Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance). Breast Cancer Research, 27(1), 1-12.
Cita Chicago Style (17a ed.)
Marks, Jeffrey R., et al. "Genomic Alterations Are Associated with Response to Aromatase Inhibitor Therapy for ER-positive Postmenopausal Ductal Carcinoma in Situ: (CALGB 40903, Alliance)." Breast Cancer Research 27, no. 1 (2025): 1-12.
Cita MLA (9a ed.)
Marks, Jeffrey R., et al. "Genomic Alterations Are Associated with Response to Aromatase Inhibitor Therapy for ER-positive Postmenopausal Ductal Carcinoma in Situ: (CALGB 40903, Alliance)." Breast Cancer Research, vol. 27, no. 1, 2025, pp. 1-12.
Precaución: Estas citas no son 100% exactas.